ClinicalTrials.gg
CompletedNCT04565483BENRAPREDUpdated Nov 13, 2026

Predictive Signature of Benralizumab Response

A Phase 4 interventional study of Benralizumab Prefilled Syringe in Asthma; Eosinophilic and Severe Asthma, sponsored by Nantes University Hospital. Completed at 20 sites in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Nantes University Hospital · Phase 4, Interventional, and Other

How we know

Updated Nov 13, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
85
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 296 studies in Asthma with a site in France — 44 open to participants now, 57 under way, 8 of them phase 3. Asthma · France.

Enrollment
146th of 204
85 · median 209
Started
2021
with 20 others
Phase 4
20 of 296
2 open now
Registered
200th of 296
by date

Among the 296 studies in Asthma with a site in France, this one is the 146th largest by enrollment of the 204 interventional ones that give a count, is one of 21 that started in 2021, is one of 20 in phase 4, and was the 200th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

44 of the 296 studies in Asthma with a site in France are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 296 studies in Asthma with a site in France, or all of them as a file.
02

Study summary

The objective of the study is to establish the predictive value of early blood gene expression signature of Benralizumab response associated with a significant reduction of the number of exacerbations in treated severe asthmatic patients.

This trial is a French, multicenter and no-randomized trial. Patients enrolled will be clinically followed for 16 months (the treatment period: 12 months and 1 month follow-up; 6 clinical visit on site and in phone call at 13 months)

03

Conditions studied

  • Asthma; Eosinophilic
  • Severe Asthma

Browse trials for

Keywords

  • severe asthma
  • therapeutic monoclonal antibody
  • personalized medicine
  • transcriptomic
  • biomarkers
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients between 18 and 75 years old.
  • Patients diagnosed with severe asthma (Chung and al, Eur Respir J 2014), i.e.:

    • asthma requiring high doses of ICS (>1000 microgram per day of Beclomethasone or equivalent) associated with LABA and/or systemic to be controlled over one year,
    • and/or uncontrolled asthma despite the later medications,
    • and/or a controlled asthma worsening after decreasing medications,
  • Documented historical reversibility of ≥12% and FEV1 gain ≥ 200 milliliter
  • ACQ-7 score ≥ 1,5 at M0.
  • ≥ 3 exacerbations in the 12 months prior to screening visit M-1.
  • Eosinophil blood count ≥ 0,3 G/L at inclusion visit or in the 12 months prior to the inclusion visit. If eosinophil blood count is ≥ 0,15 G/L and \< 0,3 G/L, an eosinophilic phenotype defined by at least 1 of the following criteria will be required:

    • Fractional Exhaled Nitric Oxide (FeNO) > 25 ppm at inclusion visit or in the 12 months prior to the inclusion visit.
    • Sputum eosinophils ≥ 3% at inclusion visit or in the 12 months prior to the inclusion visit.
  • Patients who provide written prior to participation in the study

Exclusion criteria

Exclusion Criteria:

  • Patients diagnosed with difficult-to-treat asthma and/or with uncontrolled asthma differential diagnosis according to the judgment of the investigator (e.g., vocal cord dysfunction, gastroesophageal reflux disease, granulomatous eosinophilic vasculitis, obstructive sleep apnea syndrome, hyperventilation syndrome, allergic broncho-pulmonary aspergillosis, Carrington disease, DIPNECH, asthma/ overlap syndrome).
  • Non-adherent patients to inhaled treatment (ICS + LABA).
  • Active smokers or former smokers exceeding 20 packs year.
  • Exacerbation at inclusion visit M0.
  • Active or malignancy in remission over less than 5 years.
  • Active parasitic infection or parasitic infection in the past 24 weeks.
  • to Benralizumab or to any of the of Fasenra® (histidine, histidine hydrochloride monohydrate, trehalose dihydrate, polysorbate 20)
  • Patients requiring other and immunomodulator drugs
  • Patients requiring other biotherapy than Benralizumab, with or without French's marketing authorisation in severe asthma
  • Patients requiring other biotherapy than Benralizumab that affects the immune system
  • SARS-COV2 infection
  • Pregnancy, lactation, or patients with refusing efficient method.
  • Patients under psychiatric condition altering their comprehension and their ability to give .
  • Patients already enrolled in a clinical interventional research.
  • Patients not affiliated to a health insurance plan
  • Patients under guardianship, curators or safeguard of justice
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    BENRALIZUMAB

    Patients receive BENRALIZUMAB if they meet the criteria for inclusion and non-inclusion at the inclusion visit. Injections take place at the inclusion visit, at 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months.

    Drug: Benralizumab Prefilled Syringe

Interventions

  • DrugBenralizumab Prefilled Syringe

    Patients receive BENRALIZUMAB if they meet the criteria for inclusion and non-inclusion at the inclusion visit. Injections take place at the inclusion visit, at 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months.

    Also known as: Transcriptomic

06

What researchers measure

Primary outcomes

  1. Predictive value of early blood gene expression signature of Benralizumab

    To establish the predictive value of early blood gene expression signature of Benralizumab response associated with a significant reduction of the number of exacerbations in treated severe asthmatic patients. We will evaluate an early blood gene expression signature of Benralizumab response through a clinically relevant reduction of the number of exacerbations at month 12 (M12).

    Time frame: 12 months

Secondary outcomes

  1. Molecular signature predictive of stabilization

    To establish at M0 (baseline) a molecular signature predictive of stabilization in severe asthmatic patients treated by Benralizumab. At M0 a composite blood molecular signature predictive of reduction of the exacerbation rate at M12 in severe asthmatic patients treated by Benralizumab will be assessed. The definition of stable class of patients (low category) is used as a target for the prediction. The methods used for the primary objective are applied to secondary objective using similar input data on a different 3-class prediction target.

    Time frame: 12 months

  2. The stability of the signature over time

    To evaluate the stability of the signature over time (from early at M0, M3, to late prediction at M6 and M9) considering patient trajectories. The significance of center and the relevance of time dependent modelling will be evaluated using generalised mixed models on independently established molecular response signature. It is expected a robust and reproducible gene expression to assess the inter and intra-individual trajectories of the signature over time and across centers (from early at M0 and M3, to late prediction at M6 and M9).

    Time frame: 0 month, 3 months, 6 months and 9 months

  3. The association of gene expression patterns

    To evaluate the association of gene expression patterns with both objective and subjective improvement. Correlations network between blood gene expression of Benralizumab significant response will be assessed thanks to weighted gene correlation network analysis (gene co-expression network analysis (WGCNA)) with an expected increase in forced expiratory volume at one second (FEV1) + Asthma Quality of Life Questionnaire (AQLQ) + peak-flow values and expected decrease of Asthma Control Questionnaire-7 items (ACQ-7), -6 items (ACQ-6) scores.

    Time frame: 12 months

  4. Association of gene expression patterns and clinical characteristics

    To evaluate association of gene expression patterns at M0 (baseline) and clinical characteristics of frequent exacerbations. Correlations network between blood gene expression at M0 and clinical characteristics of frequent exacerbations will be assessed thanks to WGCNA.

    Time frame: 0 months

  5. Stratification value of gene expression in severe asthma

    To assess the stratification value of gene expression in severe asthma and its correlation with clinical subgroups and clinically meaningful variables such as number of exacerbations. Correlation network between stratification value of gene expressions in severe asthma and its correlation with clinical subgroups will be assessed thanks to WGCNA. This analysis is based on pairwise correlations between genetic variables and clinical variables underlying the amount of overall variance captured by high dimensional gene expression datasets.

    Time frame: 12 months

  6. Scenario-based cost-utility analysis

    To conduct a scenario-based cost-utility analysis.Concerning cost-utility analysis, two strategies of treatment with Benralizumab will be compared: the first one will consider a strategy not using an early blood gene expression signature of Benralizumab response and the second will consider a simulated strategy using an early blood gene expression signature of Benralizumab response.

    Time frame: 12 months

07

Study locations

20 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Aug 2026, 58 months.

Of 90 non-industry phase 4 interventional studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's 58 months is above that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Oct 2026 → Aug 2026 and completion Nov 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2020
First posted
Sep 25, 2020
StartActual
Oct 11, 2021
Primary completionActual
Aug 19, 2026was Oct 2026
CompletionActual
Aug 19, 2026was Nov 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 13, 2026
Primary completion
Oct 2026→Aug 19, 2026 (actual)
Nov 13, 2026
Study completion
Nov 2026→Aug 19, 2026 (actual)
Nov 13, 2026
Enrollment
220 (estimated)→85 (actual)
Nov 13, 2026
Sponsor
Collaborators added: Ministry of Health, France; collaborators removed: Ministère de la Santé - France
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Recruiting→Completed
    Primary completion Oct 2026→Aug 19, 2026 (now actual)
    Study completion Nov 2026→Aug 19, 2026 (now actual)
    Enrollment 220 (estimated)→85 (actual)
    Sponsor Collaborators added: Ministry of Health, France; collaborators removed: Ministère de la Santé - France
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04565483
Collaborators
AstraZeneca, Ministry of Health, France
Responsible party
Sponsor
First posted
Sep 25, 2020
Start date
Oct 11, 2021
Primary completion
Aug 19, 2026
Completion
Aug 19, 2026
Last update
Nov 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion